TrialNature communications2025

TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.

Mitchell Emmers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.